TW444020B - Nucleotide analogs - Google Patents
Nucleotide analogs Download PDFInfo
- Publication number
- TW444020B TW444020B TW086110757A TW86110757A TW444020B TW 444020 B TW444020 B TW 444020B TW 086110757 A TW086110757 A TW 086110757A TW 86110757 A TW86110757 A TW 86110757A TW 444020 B TW444020 B TW 444020B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- independently
- alkenyl
- alkynyl
- aryl
- Prior art date
Links
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract description 6
- -1 alkyenylaryl Chemical group 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 125000002877 alkyl aryl group Chemical group 0.000 abstract description 4
- 125000000304 alkynyl group Chemical group 0.000 abstract description 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 4
- 125000003118 aryl group Chemical group 0.000 abstract description 4
- 125000001475 halogen functional group Chemical group 0.000 abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 4
- 125000005025 alkynylaryl group Chemical group 0.000 abstract description 3
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract description 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 3
- 230000000840 anti-viral effect Effects 0.000 abstract 3
- 125000005015 aryl alkynyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001540 azides Chemical group 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 125000000847 cytosin-1-yl group Chemical group [*]N1C(=O)N=C(N([H])[H])C([H])=C1[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
444020 A8 B8 C8 六、申請專利範圍
與L-CHR2-0-C(0)-0R /反應後回收式(1)化合物,其中B是 鳥糞嘌呤-9-基,腺嘌呤-9-基,2,6-二胺基嘌呤-9-基,2-胺基 嘌玲-9-基或其1-去氮,3-去氮,或8-氮基類似物,或b是 胞嘧啶-1-基; R1 是氫,-CH3, -CH2〇H, -CH2F,-CH = CH2, -CH2N3 或 R1 與R8連結形成-CH2-;及 R8 是氫,-CHR2-0-C(0)-0R > 或 R8 與 R1 連結形成 _CH2_; R2是H.CVCu烷基,芳基,烯基,炔基,烯芳基,炔芳 基,烷芳基,芳炔基,芳烯基或芳烷基,其係未經取代或 經鹵基,疊氮基,硝基或〇113(113爲Ci-Cu烷基)取代; R /分別是H,G-Cu烷基,芳基,烯基,炔基,烯芳基, 炔芳基,烷芳基,芳炔基,芳烯基或芳烷基,其係未經取 代或經鹵基,疊氮基,硝基或OR3取代,惟至少一個R-不 是Η ;及 L是離去基。 18.如申請專利範圍第17項之方法,該方法包括用至少 約1.0當量之l-chr2-o-c(o)-〇r/進行反應。 i 9.如申請專利範圍第17項之方法,該方法包括在有機 鹼存在下,於有機溶劑中及反應溫度約4-lOOt:進行反應約 4-72小時。 本紙張尺度適用中國國家梯準(CNS ) A4规格(210X 297公着)-4- (請先聞靖背面之注意事項再填寫本頁) 訂 Ψ. 經濟部智慧財產局員工消費合作社印製 444020 A6 B8 C8 D8 六、申請專利範圍 20. 如申請專利範圍第17項之方法 形成鹽類後沈澱回收。 21. 如申請專利範圍第20項之方法 酸、磷酸、乳酸或檸檬酸。 22.—種具有下式之化合物 其中式(1)化合物 其中該鹽類得自硫
〇 〇、/ 3 CH2〆 c 、CH3 •〇-CH2^C c -ch3 0 \h. (請先閲请背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本纸張尺度適用中國國家揉準(CNS ) A4規格(210X297公釐)-5 -
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2270896P | 1996-07-26 | 1996-07-26 | |
US68683896A | 1996-07-26 | 1996-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW444020B true TW444020B (en) | 2001-07-01 |
Family
ID=26696272
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW089123708A TW470748B (en) | 1996-07-26 | 1997-08-21 | Nucleotide analogs |
TW086110757A TW444020B (en) | 1996-07-26 | 1997-08-21 | Nucleotide analogs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW089123708A TW470748B (en) | 1996-07-26 | 1997-08-21 | Nucleotide analogs |
Country Status (4)
Country | Link |
---|---|
JP (6) | JP4033494B2 (zh) |
CA (1) | CA2261619C (zh) |
TW (2) | TW470748B (zh) |
WO (1) | WO1998004569A1 (zh) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4033494B2 (ja) * | 1996-07-26 | 2008-01-16 | ギリヤド サイエンシーズ, インコーポレイテッド | ヌクレオチドアナログ |
EP1243593B1 (en) * | 1997-07-25 | 2005-09-21 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
PT1256584E (pt) * | 1997-07-25 | 2004-12-31 | Gilead Sciences Inc | Processo para a preparacao de adefovir-dipivoxil |
BR9811045A (pt) * | 1997-07-25 | 2000-08-22 | Gilead Sciences Inc | Composição de análogo de nucleotìdeo e processo de sìntese |
CA2335617C (en) * | 1998-06-24 | 2009-12-15 | Emory University | Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
AU2001282941C1 (en) * | 2000-07-21 | 2016-12-22 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
BR0309557A (pt) | 2002-04-26 | 2005-03-01 | Gilead Sciences Inc | Inibidores da transcriptase reversa não nucleosìdeos |
ATE398455T1 (de) | 2003-01-14 | 2008-07-15 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
CN101410120A (zh) * | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
AU2004233897A1 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
CN1805966B (zh) | 2003-06-16 | 2013-03-13 | 捷克科学院有机化学和生物化学研究所 | 作为抗病毒核苷酸类似物的含膦酸酯基团的嘧啶化合物 |
EP1678321A1 (en) | 2003-10-24 | 2006-07-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
US7427624B2 (en) | 2003-10-24 | 2008-09-23 | Gilead Sciences, Inc. | Purine nucleoside phosphorylase inhibitory phosphonate compounds |
NZ547907A (en) | 2003-12-22 | 2010-07-30 | Gilead Sciences Inc | 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity |
MXPA06007095A (es) * | 2003-12-22 | 2006-09-04 | Gilead Sciences Inc | Conjugados de fosfonato inhibidores de cinasa. |
UA88313C2 (ru) | 2004-07-27 | 2009-10-12 | Гилиад Сайенсиз, Инк. | Фосфонатные аналоги соединений ингибиторов вич |
US20100216822A1 (en) * | 2005-06-13 | 2010-08-26 | Brightgene Bio-Medical Technology Co., Ltd. | Nucleotide Analogue Prodrug and the Preparation Thereof |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
CN101940571A (zh) | 2007-04-13 | 2011-01-12 | 南方研究所 | 抗血管生成剂和使用方法 |
US20090270352A1 (en) * | 2007-05-22 | 2009-10-29 | Ultimorphix Technologies B.V. | Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal |
WO2009064174A1 (en) * | 2007-11-14 | 2009-05-22 | Ultimorphix Technologies B.V. | Polymorphic form of tenofovir disoproxil fumarate, method for its preparation and use |
JP5757860B2 (ja) * | 2008-04-25 | 2015-08-05 | シプラ・リミテッド | 結晶形態のテノホビルジソプロキシル及びその製造方法 |
EA018308B1 (ru) | 2008-07-08 | 2013-07-30 | Джилид Сайэнс, Инк. | Соли соединений ингибиторов вич |
CN102093422B (zh) | 2009-12-10 | 2015-02-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 无环核苷膦酸酯衍生物及其医药用途 |
US20140073607A1 (en) * | 2011-05-10 | 2014-03-13 | Okapi Sciences Nv | Compounds for use in the treatment of feline retroviral infections |
US8754065B2 (en) | 2011-08-16 | 2014-06-17 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
CN103626802A (zh) * | 2012-08-23 | 2014-03-12 | 重庆药友制药有限责任公司 | 一种制备替诺福韦的新方法 |
CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
US9227990B2 (en) | 2012-10-29 | 2016-01-05 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
EP2860184B1 (en) | 2013-10-09 | 2018-08-29 | Zentiva, k.s. | Dihydrogenphosphate salt of Tenofovir disoproxil |
EP2860185A1 (en) | 2013-10-09 | 2015-04-15 | Zentiva, k.s. | An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof |
TWI660965B (zh) * | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
CN107805202A (zh) * | 2017-12-01 | 2018-03-16 | 内蒙古圣氏化学股份有限公司 | 一种氯甲基异丙基碳酸酯连续化反应装置及方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL84477A (en) * | 1986-11-18 | 1995-12-08 | Bristol Myers Squibb Co | History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them |
EP0481214B1 (en) * | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
GB9026164D0 (en) * | 1990-12-01 | 1991-01-16 | Beecham Group Plc | Pharmaceuticals |
AU691527B2 (en) * | 1993-09-17 | 1998-05-21 | Gilead Sciences, Inc. | Nucleotide analogs |
JP4033494B2 (ja) * | 1996-07-26 | 2008-01-16 | ギリヤド サイエンシーズ, インコーポレイテッド | ヌクレオチドアナログ |
-
1997
- 1997-07-25 JP JP50831898A patent/JP4033494B2/ja not_active Expired - Lifetime
- 1997-07-25 WO PCT/US1997/013244 patent/WO1998004569A1/en not_active Application Discontinuation
- 1997-07-25 CA CA002261619A patent/CA2261619C/en not_active Expired - Lifetime
- 1997-08-21 TW TW089123708A patent/TW470748B/zh not_active IP Right Cessation
- 1997-08-21 TW TW086110757A patent/TW444020B/zh not_active IP Right Cessation
-
2007
- 2007-07-09 JP JP2007180398A patent/JP2007297406A/ja not_active Withdrawn
-
2010
- 2010-10-15 JP JP2010233086A patent/JP2011016847A/ja not_active Withdrawn
-
2014
- 2014-04-15 JP JP2014083387A patent/JP2014159450A/ja not_active Withdrawn
-
2015
- 2015-04-28 JP JP2015091141A patent/JP2015164934A/ja not_active Withdrawn
-
2016
- 2016-10-31 JP JP2016212748A patent/JP2017031212A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1998004569A1 (en) | 1998-02-05 |
CA2261619C (en) | 2006-05-23 |
JP2015164934A (ja) | 2015-09-17 |
CA2261619A1 (en) | 1998-02-05 |
JP4033494B2 (ja) | 2008-01-16 |
JP2017031212A (ja) | 2017-02-09 |
JP2007297406A (ja) | 2007-11-15 |
JP2000515866A (ja) | 2000-11-28 |
TW470748B (en) | 2002-01-01 |
JP2014159450A (ja) | 2014-09-04 |
JP2011016847A (ja) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW444020B (en) | Nucleotide analogs | |
EP3150600B1 (en) | Dihydropyrimido loop derivative as hbv inhibitor | |
JPH0586792B2 (zh) | ||
WO2006034583A1 (en) | Alkynyl based dervatives of benzophenone as non-nucleoside reverse transcriptase inhibitors | |
JP5863789B2 (ja) | ピラゾール誘導体の製造方法 | |
JP5805880B2 (ja) | 1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)−プロパ−2−エン−1−オン塩酸塩の製造方法および該方法で用いられる中間体 | |
SK743188A3 (en) | 2',3'-dideoxy-2'-fluoronucleosides, method of production and pharmaceutical agents containing them | |
IE59713B1 (en) | Amino-thiazole and oxazole derivatives | |
CA2436665A1 (en) | Nucleic acid derivatives | |
JP4336820B2 (ja) | オリゴヌクレオチドプローブ | |
US8119800B2 (en) | Processes for preparing HIV reverse transcriptase inhibitors | |
JP7109056B2 (ja) | S-icaリボシルホモシステインの製造方法 | |
JPS5818346A (ja) | N−置換アクリルアミド及びメタクリルアミドの製造方法 | |
CS259896B2 (en) | Method of aryloxypropanolamine's new salts production with diphenyl acetic acid | |
KR830007510A (ko) | 심장질환 치료제의 제조방법 | |
DE69526332T2 (de) | Indol-derivate | |
YU47906B (sh) | Proces za sintezu optički aktivnih aminokiselina | |
NL8007126A (nl) | Werkwijze ter bereiding van watervrij 2-hydroxy-3-chloorpropyltrimethylammoniumchloride. | |
CA2883263C (en) | Photocleavable linker molecules with diarylsulphid backbone for transient bioconjugate synthesis | |
US2856405A (en) | Mecuration products of 1-(2-pyrimidyl)-3-allylurea | |
JPH013178A (ja) | アミン誘導体の製造方法 | |
WO1996034861A1 (fr) | Nouveau procede de n2-tritylation de cycles tetrazole | |
JP2017178811A (ja) | γターン構造を有する化合物及びそれを用いたLSD1阻害剤 | |
JP4004082B2 (ja) | 環状ニトログアニジン誘導体の製造法 | |
CA1067099A (en) | Process for the production of substituted benzyl cyanides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |